We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BIOTECH FIRMS COULD BENEFIT FROM STOCK OPTION REFORM
BIOTECH FIRMS COULD BENEFIT FROM STOCK OPTION REFORM
July 23, 2004
Legislation that would require companies to expense the stock options of only the five highest-paid company executives was passed by the House last week — an action that delighted the biotechnology industry, which had opposed another government proposal requiring companies to expense all employee stock options.